李時沆

  • 律师
  • T. +82-2-3404-1261
  • F. +82-2-3404-0804
  • E. shihang.lee@bkl.co.kr

介绍

Shihang Lee is a legal expert specializing in healthcare regulation and data protection. He focuses on establishing integrated regulatory strategies for the digital transformation of the healthcare industry.

Global Research Data Privacy & AI Regulation: Shihang excels in resolving complex legal challenges at the intersection of medical, bioethics, and privacy laws. He is particularly recognized for his ability to navigate high-stakes regulatory uncertainties, supporting the development of robust data governance frameworks for global multi-center clinical trials, cross-border data transfers, and AI model training using Real-World Data (RWD).

Healthcare Regulatory & Crisis Management: Drawing on his experience at the Ministry of Food and Drug Safety (MFDS), Shihang provides practical, end-to-end solutions throughout the product life cycle – from business licensing and GXP compliance to labeling, advertising, and post-market surveillance. He has a proven track record in risk mitigation and crisis management, representing clients in significant administrative and criminal proceedings that impact business continuity.

Bio & Digital Product Commercialization Strategy: Leveraging his life sciences background and extensive secondment experience at multinational corporations, he bridges the gap between R&D and legal functions. He provides strategic counsel on the commercialization of digital health business models and innovative pipelines, ensuring they meet both global business objectives and local regulatory requirements. 

履历

2021-至今 Bae, Kim & Lee LLC
2019-2021 DLG Law Corporation
2016-2019 Public Service Advocate, Ministry of Justice
2016-2017 Ministry of Food and Drug Safety (Secondment)
其他经历
2025-至今 Committee Member, ELSI Committee, National Bio Big Data Project (BIKO), KHIDI
2025-至今 Committee Member, Data Governance Committee, KOBIC Biobank
2024-至今 Ombudsman, Ministry of Food and Drug Safety (MFDS)
2021-至今 Expert Member, Health Data Review Committee, Korea Health Information Service (KHIS)
2019-2020 External Committee Member, Institutional Bioethics Committee, Ajou University Hospital

主要业务案例

Advised on and secured the ICT Regulatory Sandbox (Special Demonstration) approval for a cross-border Federated Learning platform between Seoul National University Hospital and Mayo Clinic
Provided strategic counsel on the data governance and consent frameworks for the National Integrated Bio-Big Data Project (BIKO)
Successfully represented 34 domestic pharmaceutical companies in landmark litigations regarding NDMA impurities in Valsartan products, prevailing in both the High Court and the Supreme Court
Defended pharmaceutical companies in Special Investigation Team (SIT) probes by the MFDS and criminal proceedings concerning GMP violations and Narcotics Control Act compliance
Conducted regulatory due diligence (LDD) for M&A and equity investments in biotech, EMR, and CRO sectors, identifying critical licensing risks
Global Research Data Privacy & AI Regulation
Advised on and secured the ICT Regulatory Sandbox (Special Demonstration) approval for a cross-border Federated Learning platform between Seoul National University Hospital and Mayo Clinic
Provided strategic counsel on the data governance and consent frameworks for the National Integrated Bio-Big Data Project (BIKO)
Advised the Korea Health Information Service (KHIS) on the amendment of national standards for bio-health data terminology and transmission (FHIR/HL7)
Conducted comprehensive legal assessments on utilizing health data for AI model training and RWE-based research for leading medical device and IVD companies
Spearheaded enterprise-wide data privacy compliance projects for global healthcare leaders including J&J, Kenvue, Roche Diagnostics, and Novo Nordisk
Managed cross-border data transfer issues and supported responses to National Assembly audits (Health and Welfare Committee) for genomics and digital diagnostic firms
Healthcare Regulatory & Crisis Management
Successfully represented 34 domestic pharmaceutical companies in landmark litigations regarding NDMA impurities in Valsartan products, prevailing in both the High Court and the Supreme Court
Defended pharmaceutical companies in Special Investigation Team (SIT) probes by the MFDS and criminal proceedings concerning GMP violations and Narcotics Control Act compliance
Directed enterprise-wide compliance audits and transparency reporting (Sunshine Act) for various multinational pharmaceutical entities
Defended major retail corporations in administrative actions involving labeling violations of imported foods and healthcare products
Advised global medical device companies on regulatory investigations related to grievance handling, adverse event reporting, and GCP compliance
Reviewed issues relating to cross-border data transfers for genomic analysis and digital in vitro diagnostics companies, and supported responses to National Assembly audits before the Health and Welfare Committee
Bio & Digital Product Commercialization Strategy
Formulated Go-To-Market (GTM) strategies for innovative digital and combination products, focusing on the linkage between regulatory approval and pricing/reimbursement (P&R)
Conducted regulatory due diligence (LDD) for M&A and equity investments in biotech, EMR, and CRO sectors, identifying critical licensing risks
Negotiated and structured complex Data Transfer Agreements (DTA) and Collaborative R&D Agreements between multinational healthcare firms and top-tier Korean hospitals
Advised on the regulatory architecture for establishing innovative healthcare and beauty complexes within major retail platforms

学历

2016 Yonsei University Law School (J.D.)
2011 University of California, Berkeley (B.S., B.A.)

主要社会活动

著作
South Korea Third Country Assessment Contribution (OneTrust DataGuidance, 2021-Present)
ICLG: Digital Health - South Korea (International Comparative Legal Guides, 2020)
活动
Lecturer, Data & AI Session (KMDIA Education Curriculum, 2025)
Lecturer, Bio Big Data Session (Cheongram Bio Academy, 2025)
Korea Panel, IPMPC ASAPC Roundtable and Consortium (2024-2026)
Presenter, Data & AI Session (KRPIA EBP Workshop, 2023, 2025)
Presenter, Rebate Session (H1 2023) and Data & AI Session (H1 2025) (KPBMA Ethics & Compliance Workshop)
Developed lecture materials for the Medical Representative (MR) Certification Program (KPBMA Education Curriculum, 2022)

资格

2016 Korea